Channels
All News
In Focus
Special
AI
Bioregnum
Biotech Voices
Cell/Gene Tx
China
Coronavirus
Deals
Diagnostics
Discovery
FDA+
Financing
Health Tech
Law
Letters to the Editor
Manufacturing
Marketing
Nikkei Biotechnology
Opinion
Outsourcing
Peer Review
People
Pharma
R&D
Startups
Weekly
Webinars
Biopharma Jobs
More
Work at Endpoints
Letter to Editors
Editorial Standards
IPO Tracker
Webinars
Events
Sponsored Posts
Advertise
Privacy Policy
Endpoints Merch
About Us
Help
SIGN UP
LOG IN
R&D channel feed
Rhythm says oral rare obesity drug clears Phase 2 test, plans tweaks to formulation
7 hours ago
AstraZeneca’s Alexion inks AAV capsid deal with JCR Pharma
8 hours ago
Cell/Gene Tx
'CRISPR Cures' center launches with $20M to make customized gene editing therapies
23 hours ago
Cell/Gene Tx
ProKidney's stock shoots higher after mixed Phase 2 data
Yesterday
Exclusive: Startup raises $45M for universal flu vaccines made with mRNA
Yesterday
Startups
Singaporean biotech gets China thumbs-up for study of potentially curative HBV cell therapy
Yesterday
China
Cell/Gene Tx
Clinician groups sue RFK Jr. and HHS over Covid-19 vaccine recommendation changes
2 days ago
Pharma
FDA+
Cogent’s mastocytosis drug hits ‘home run’ in registrational mid-stage trial
2 days ago
Compromised drug lot impacts Jasper's chronic hives study, stock falls
2 days ago
Manufacturing
Apogee reports Phase 2 win for eczema drug that could challenge Dupixent and Ebglyss
2 days ago
Novartis' Cosentyx fails Phase 3 study for autoimmune disease
6 days ago
Pharma
Structure in partnering talks for GLP-1 pill as mid-stage readout nears
6 days ago
4DMT lays off staff, reshuffles team as it doubles down on Phase 3 plans
6 days ago
People
Bristol Myers' China partner touts Phase 3 success for EGFRxHER3 bispecific ADC
Last week
China
Vyne stops enrolling early-stage psoriasis study following clinical hold lift, early data
Last week
AbbVie cans oral ulcerative colitis drug from Landos buyout
Last week
Pharma
Shionogi, BioVersys team up on antibiotics for lung disease in deal worth up to $614M
Last week
Deals
PBM reforms fail to make the cut as Senate passes Trump’s megabill
Last week
Pharma
FDA+
Advocates urge J&J to ‘put everything on the table’ for gene therapy despite failed trial
Last week
Cell/Gene Tx
In Focus
Beckley touts positive mid-stage psychedelic data following atai merger plans
Last week
Protagonist unveils 'triple-G' obesity pill, but human trials are nearly a year away
Last week
Pfizer ends Phase 1b/2 trial for final Trillium CD47 drug
Last week
Arcturus claims Phase 2 success in first data since shift to mRNA therapeutics, investor reaction is muted
Last week
CBER chief Prasad suggests Covid vaccine harms may outweigh benefits in 'low-risk populations'
Last week
Pharma
FDA+
1
2
3
4
Next page
Last page